Progress, pharmacokinetics and future perspectives of luteolin modulating signaling pathways to exert anticancer effects: A review
Open Access
- 23 August 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (34) , e39398
Abstract
Luteolin (3, 4, 5, 7-tetrahydroxyflavone) are natural flavonoids widely found in vegetables, fruits and herbs, with anti-tumor, anti-inflammatory and antioxidant effects, and also play an anti-cancer effect in various cancers such as lung, breast, prostate, and liver cancer, etc. Specifically, the anti-cancer mechanism includes regulation of various signaling pathways to induce apoptosis of tumor cells, inhibition of tumor cell proliferation and metastasis, anti-angiogenesis, regulation of immune function, synergistic anti-cancer drugs and regulation of reactive oxygen species levels of tumor cells. Specific anti-cancer mechanisms include regulation of various signaling pathways to induce apoptosis, inhibition of tumor cell proliferation and metastasis, anti-angiogenesis, reversal of epithelial-mesenchymal transition, regulation of immune function, synergism with anti-cancer drugs and regulation of reactive oxygen species levels in tumor cells. This paper integrates the latest cutting-edge research on luteolin and combines it with the prospect of future clinical applications, aiming to explore the mechanism of luteolin exerting different anticancer effects through the regulation of different signaling pathways, so as to provide a practical theoretical basis for the use of luteolin in clinical treatment and hopefully provide some reference for the future research direction of luteolin.Keywords
Funding Information
- Postgraduate Research & Practice Innovation Program of Jiangsu Province (SJCX24_2060)
- 2021 Jiangsu Provincial Health and Health Commission Medical Research Guidance Project (Z2021087)
- The Special Funds for Science Development of the Clinical Teaching Hospitals of Jiangsu Vocational College of Medicine (20219105)
- 2021 Yancheng Medical Science and Technology Development Plan Project (YK2021060)
- Nantong University's 2023 Academic Level Research Project (YXY-Z2023008)
- 2023 Nantong University Clinical Medicine Special Research Fund Project (2023JZ022)
This publication has 128 references indexed in Scilit:
- Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cellsBiochemical and Biophysical Research Communications, 2008
- A Critical Role of Luteolin-Induced Reactive Oxygen Species in Blockage of Tumor Necrosis Factor-Activated Nuclear Factor-κB Pathway and Sensitization of Apoptosis in Lung Cancer CellsMolecular Pharmacology, 2007
- Absorption and Excretion of Luteolin and Apigenin in Rats after Oral Administration of Chrysanthemum morifolium ExtractJournal of Agricultural and Food Chemistry, 2006
- Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cellsCarcinogenesis, 2006
- Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K–Akt pathwaysChemico-Biological Interactions, 2006
- BRCA1 and c-Myc Associate to Transcriptionally Repress Psoriasin, a DNA Damage–Inducible GeneCancer Research, 2005
- The MAPK signalling pathways and colorectal cancerThe Lancet Oncology, 2005
- Luteolin Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis; Inhibition of Endothelial Cell Survival and Proliferation by Targeting Phosphatidylinositol 3′-Kinase ActivityCancer Research, 2004
- Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolismArchives of Biochemistry and Biophysics, 2003
- Dietary agents in cancer prevention: flavonoids and isoflavonoidsPharmacology & Therapeutics, 2001